Arena Pharma (ARNA) Misses Q2 EPS by 1c
Get Alerts ARNA Hot Sheet
Price: $99.98 --0%
Financial Fact:
Net loss per share allocable to common stockholders, diluted: -0.05
Today's EPS Names:
ESCA, LICT, NKSH, More
Financial Fact:
Net loss per share allocable to common stockholders, diluted: -0.05
Today's EPS Names:
ESCA, LICT, NKSH, More
Join SI Premium – FREE
Arena Pharma (NASDAQ: ARNA) reported Q2 EPS of ($0.11), $0.01 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $9.5 million versus the consensus estimate of $10.44 million.
2016 Corporate Guidance Update
- R&D expenses between $78 to $84 million, including non-cash expenses of approximately $9 million
- G&A expenses between $27 to $33 million, including non-cash expenses of approximately $7 million
- The Company believes the costs reductions and strategic shift in priorities will allow it to manage its cash through completion of Phase 2 clinical trials for its three internal clinical stage programs.
For earnings history and earnings-related data on Arena Pharma (ARNA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BayCom Corp (BCML) Misses Q1 EPS by 4c
- Southern First Bancshares, Inc. (SFST) Misses Q1 EPS by 8c
- PPG Industries (PPG) Reports In-Line Q1 EPS, offers outlook
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!